OBJECTIVE: To probe into the efficacy of Xiao’er Xiaoji Zhike granules combined with montelukast sodium in the treatment of cough variant asthma（CVA） in children. METHODS: Totally 96 children with CVA admitted into the hospital from Mar. 2020 to Dec. 2021 were extracted to be divided into the control group and the research group via the two-color ball method

with 48 cases in each group. The control group was treated with montelukast sodium

while the research group received Xiao’er Xiaoji Zhike granules. The efficacy

levels of inflammatory factors [interleukin-6（IL-6）

C-reactive protein（CRP） and tumor necrosis factor-α（TNF-α）]

pulmonary function [peak expiratory flow（PEF）

forced expiratory volume at one second（FEV

1

） and forced vital capacity（FVC）] and related scale scores before and after treatment

the incidence of adverse drug reactions during treatment in two groups were observed. RESULTS: The total clinical effective rate of the research group was 93.75%（45/48）

higher than 75.00%（36/48） of the control group

the difference was statistically significant（P

<

0.05）. After 7 d of treatment

the levels of IL-6

CRP and TNF-α in two groups decreased compared with before treatment

and the research group was lower than the control group

with statistically significant differences（P

<

0.05）. The PEF

FEV

1

and FVC of two groups after treatment were higher than those before treatment

and the research group was higher than the control group

the differences were statistically significant（P

<

0.05）. After 7 d of treatment

the Leicester Cough Quality of life questionnaire score

Asthma Control Test score and Bronchial Asthma Medication Adherence Scale score in two groups after treatment were higher than those before treatment

and the research group was higher than the control group

the differences were statistically significant（P

<

0.05）. There were no severe adverse drug reactions in both groups. CONCLUSIONS: Xiao’er Xiaoji Zhike granules combined with montelukast sodium can effectively alleviate the cough symptoms

improve lung function and reduce the level of inflammatory factors in children with CVA.